Header Logo

Adam S Asch

TitleProf
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentMedicine Hematology/Oncology
AddressSOCC 6 FL
800 NE 10th St
Oklahoma City OK 73104
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01NS043883     (ASCH, ADAM S)Sep 30, 2001 - Jul 31, 2006
    NIH
    INDUCTION AND MAINTENANCE OF PLURIPOTENT-PLASTIC STATE
    Role: Principal Investigator
    R01DK048698     (ASCH, ADAM S)Jan 1, 1997 - Dec 31, 2002
    NIH
    ENDOTHELIAL CELL-STEM CELL INTERACTIONS
    Role: Principal Investigator
    R01HL044389     (ASCH, ADAM S)Aug 1, 1991 - Jul 31, 1995
    NIH
    STRUCTURE/FUNCTION OF THE TSP--CD36 SYSTEM
    Role: Principal Investigator
    K04HL002541     (ASCH, ADAM S)Dec 15, 1990 - Nov 30, 1995
    NIH
    STRUCTURE AND FUNCTION OF THE TSP-GPIV SYSTEM
    Role: Principal Investigator
    K08HL001567     (ASCH, ADAM S)Aug 1, 1985 - Jul 31, 1990
    NIH
    THE CELLULAR BIOLOGY OF THROMBOSPONDIN
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Maakaron J, Asch AS, Popplewell L, Collins GP, Flinn IW, Ghosh N, Keane C, Ku M, Mehta A, Roschewski M, Hacohen-Kleiman G, Huo Y, Zhang Y, Renard C, Smith SM, Advani RH. Magrolimab Plus Rituximab with/without Chemotherapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood Adv. 2024 Sep 18. PMID: 39293083.
      Citations:    Fields:    
    2. Singh SP, Pathuri G, Asch AS, Rao CV, Madka V. Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models. Cells. 2024 Aug 31; 13(17). PMID: 39273033; PMCID: PMC11394313.
      Citations:    Fields:    Translation:HumansAnimalsCells
    3. Davis O, Lessani C, Kasht R, Cohoon A, Ibrahimi S, Asch A, Day S, Al-Juhaishi T. Impact of Primary Disease Site of Involvement by Early-Stage Follicular Lymphoma on Patient Outcomes. Clin Lymphoma Myeloma Leuk. 2024 Jul 15. PMID: 39147647.
      Citations:    Fields:    
    4. Soumerai JD, Diefenbach CS, Jagadeesh D, Asch A, Kumar A, Tsai ML, Jandl TA, Lossos IS, Kenkre VP, Awan F, Novotny W, Huang J, Miao L, Rajagopalan P, Ghalie RG, Zelenetz AD. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. Br J Haematol. 2024 Mar 19. PMID: 38500476.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    5. Davis O, Truong D, Day S, Pandey M, Ibrahimi S, Khawandanah M, Holter-Chakrabarty J, Asch A, Al-Juhaishi T. Impact of primary organ site of involvement by peripheral T-cell lymphoma not otherwise specified on survival. Cancer Med. 2023 Dec 11. PMID: 38073461.
      Citations: 1     Fields:    Translation:Humans
    6. Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med. 2023 Oct 19. PMID: 37857711.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    7. Daver NG, Vyas P, Kambhampati S, Al Malki MM, Larson RA, Asch AS, Mannis G, Chai-Ho W, Tanaka TN, Bradley TJ, Jeyakumar D, Wang ES, Sweet K, Kantarjian HM, Garcia-Manero G, Komrokji R, Xing G, Ramsingh G, Renard C, Zeidner JF, Sallman DA. Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. J Clin Oncol. 2023 Sep 13; JCO2202604. PMID: 37703506.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    8. Pratz KW, Cherry M, Altman JK, Cooper BW, Podoltsev NA, Cruz JC, Lin TL, Schiller GJ, Jurcic JG, Asch A, Wu R, Hill JE, Gill SC, James AJ, Rich ES, Hasabou N, Perl AE, Levis MJ. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. J Clin Oncol. 2023 Jun 28; JCO2202721. PMID: 37379495.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    9. Corbin JM, Georgescu C, Wang L, Wren JD, Bieniasz M, Xu C, Asch AS, Ruiz Echevarr?a MJ. An unbiased seed-based RNAi selection screen identifies small RNAs that inhibit androgen signaling and prostate cancer cell growth. Mol Ther Nucleic Acids. 2023 Sep 12; 33:257-272. PMID: 37554515; PMCID: PMC10404560.
      Citations: 2     
    10. Patel MR, Donnellan W, Byrne M, Asch AS, Zeidan AM, Baer MR, Fathi AT, Kuykendall AT, Zheng F, Walker C, Cheng L, Marando C, Savona MR. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2023 May 15. PMID: 37290996.
      Citations: 1     Fields:    Translation:HumansAnimalsCTClinical Trials
    11. Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. J Clin Oncol. 2023 Mar 08; JCO2201794. PMID: 36888930.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    12. MacDougall K, Day S, Hall S, Zhao D, Pandey M, Ibrahimi S, Khawandanah M, Chakrabarty JH, Asch A, Nipp R, Al-Juhaishi T. Impact of Race and Age and their Interaction on Survival Outcomes in Patients With Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):379-384. PMID: 36813625.
      Citations: 2     Fields:    Translation:Humans
    13. Assouline S, Michaelis LC, Othus M, Hay AE, Walter RB, Jacoby MA, Schroeder MA, Uy GL, Law LY, Cheema F, Sweet KL, Asch AS, Liu JJ, Moseley AB, Maher T, Kingsbury LL, Fang M, Radich J, Little RF, Erba HP. A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leuk Lymphoma. 2023 02; 64(2):473-477. PMID: 36517990.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    14. Borogovac A, Tarasco E, Kremer Hovinga JA, Friedman KD, Asch AS, Vesely SK, Prodan CI, Terrell DR, George JN. Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. Blood. 2022 08 18; 140(7):785-789. PMID: 35584244.
      Citations: 3     Fields:    Translation:Humans
    15. Rao CV, Xu C, Zhang Y, Asch AS, Yamada HY. Genomic instability genes in lung and colon adenocarcinoma indicate organ specificity of transcriptomic impact on Copy Number Alterations. Sci Rep. 2022 07 11; 12(1):11739. PMID: 35817785.
      Citations:    Fields:    Translation:HumansCells
    16. Pagel JM, Soumerai JD, Reddy N, Jagadeesh D, Stathis A, Asch A, Salman H, Kenkre VP, Iasonos A, Llorin-Sangalang J, Li J, Zelenetz AD. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022 08; 23(8):1021-1030. PMID: 35835137.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    17. Borogovac A, Keruakous A, Bycko M, Holter Chakrabarty J, Ibrahimi S, Khawandanah M, Selby GB, Yuen C, Schmidt S, Autry MT, Al-Juhaishi T, Wieduwilt MJ, Asch AS. Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center. Bone Marrow Transplant. 2022 06; 57(6):1025-1027. PMID: 35411106.
      Citations: 16     Fields:    Translation:Humans
    18. Keruakous AR, Asch A, Aljumaily R, Zhao D, Yuen C. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma. Transpl Immunol. 2022 04; 71:101544. PMID: 35093506.
      Citations: 4     Fields:    Translation:HumansCells
    19. Keruakous AR, Day S, Garcia-Ramiu K, Yarbrough M, Asch AS. Research Staff Perspectives on Cancer Clinical Trials and Barriers to Recruitment: A Qualitative Research. Cureus. 2021 Aug; 13(8):e17202. PMID: 34540430.
      Citations: 2     
    20. Rao CV, Xu C, Farooqui M, Zhang Y, Asch AS, Yamada HY. Survival-Critical Genes Associated with Copy Number Alterations in Lung Adenocarcinoma. Cancers (Basel). 2021 May 25; 13(11). PMID: 34070461.
      Citations: 2     
    21. Corbin JM, Georgescu C, Wren JD, Xu C, Asch AS, Ruiz-Echevarría MJ. Seed-mediated RNA interference of androgen signaling and survival networks induces cell death in prostate cancer cells. Mol Ther Nucleic Acids. 2021 Jun 04; 24:337-351. PMID: 33850637.
      Citations: 5     
    22. Keruakous AR, Balakrishna P, Schmidt SA, Autry MT, Asch A. Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant. Ann Hematol. 2021 06; 100(6):1629-1630. PMID: 33433650.
      Citations: 1     Fields:    Translation:Humans
    23. Rao CV, Farooqui M, Madhavaram A, Zhang Y, Asch AS, Yamada HY. GSK3-ARC/Arg3.1 and GSK3-Wnt signaling axes trigger amyloid-ß accumulation and neuroinflammation in middle-aged Shugoshin 1 mice. Aging Cell. 2020 10; 19(10):e13221. PMID: 32857910.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    24. Assi HA, Asch AS, Machiorlatti M, Vesely SK, Ibrahimi S. Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future Sci OA. 2020 Jun 25; 6(7):FSO581. PMID: 32802390.
      Citations: 8     
    25. Rao CV, Asch AS, Carr DJJ, Yamada HY. "Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease. Aging Cell. 2020 03; 19(3):e13109. PMID: 31981470.
      Citations: 26     Fields:    Translation:HumansAnimals
    26. Madka V, Kumar G, Pathuri G, Zhang Y, Lightfoot S, Asch AS, Mohammed A, Steele VE, Rao CV. Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model. Cancer Prev Res (Phila). 2020 02; 13(2):185-194. PMID: 31699708.
      Citations: 6     Fields:    Translation:HumansAnimals
    27. Georgescu C, Corbin JM, Thibivilliers S, Webb ZD, Zhao YD, Koster J, Fung KM, Asch AS, Wren JD, Ruiz-Echevarría MJ. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer. BMC Cancer. 2019 May 06; 19(1):423. PMID: 31060542.
      Citations: 5     Fields:    Translation:HumansCells
    28. Rao CV, Farooqui M, Asch AS, Yamada HY. Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model. Cell Cycle. 2018; 17(19-20):2321-2334. PMID: 30231670.
      Citations: 4     Fields:    Translation:Animals
    29. Rao CV, Farooqui M, Zhang Y, Asch AS, Yamada HY. Spontaneous development of Alzheimer's disease-associated brain pathology in a Shugoshin-1 mouse cohesinopathy model. Aging Cell. 2018 08; 17(4):e12797. PMID: 29943428.
      Citations: 15     Fields:    Translation:Animals
    30. Mohammed A, Janakiram NB, Madka V, Li M, Asch AS, Rao CV. Current Challenges and Opportunities for Chemoprevention of Pancreatic Cancer. Curr Med Chem. 2018; 25(22):2535-2544. PMID: 28183260.
      Citations: 4     Fields:    Translation:HumansAnimals
    31. Rao CV, Mohammed A, Asch AS, Janakiram NB. Immunoprevention of Pancreatic Cancer. Curr Med Chem. 2018; 25(22):2576-2584. PMID: 28240168.
      Citations: 2     Fields:    Translation:HumansCells
    32. Janakiram NB, Mohammed A, Bryant T, Ritchie R, Stratton N, Jackson L, Lightfoot S, Benbrook DM, Asch AS, Lang ML, Rao CV. Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice. Immunology. 2017 09; 152(1):36-51. PMID: 28419443.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    33. Rao CV, Pal S, Mohammed A, Farooqui M, Doescher MP, Asch AS, Yamada HY. Biological effects and epidemiological consequences of arsenic exposure, and reagents that can ameliorate arsenic damage in vivo. Oncotarget. 2017 Aug 22; 8(34):57605-57621. PMID: 28915699.
      Citations: 25     Fields:    
    34. Rao CV, Asch AS, Yamada HY. Frequently mutated genes/pathways and genomic instability as prevention targets in liver cancer. Carcinogenesis. 2017 01; 38(1):2-11. PMID: 27838634.
      Citations: 75     Fields:    Translation:HumansCells
    35. Rao CV, Asch AS, Yamada HY. Emerging links among Chromosome Instability (CIN), cancer, and aging. Mol Carcinog. 2017 03; 56(3):791-803. PMID: 27533343.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    36. Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol. 2016 Oct; 175(2):281-289. PMID: 27448091.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    37. Datla US, Scovill NC, Brokamp AJ, Kim E, Asch AS, Lee MH. Role of PUF-8/PUF protein in stem cell control, sperm-oocyte decision and cell fate reprogramming. J Cell Physiol. 2014 Oct; 229(10):1306-11. PMID: 24638209.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    38. Kobet RA, Pan X, Zhang B, Pak SC, Asch AS, Lee MH. Caenorhabditis elegans: A Model System for Anti-Cancer Drug Discovery and Therapeutic Target Identification. Biomol Ther (Seoul). 2014 Sep; 22(5):371-83. PMID: 25414766.
      Citations: 15     
    39. Chen X, Corbin JM, Tipton GJ, Yang LV, Asch AS, Ruiz-Echevarría MJ. The TMEFF2 tumor suppressor modulates integrin expression, RhoA activation and migration of prostate cancer cells. Biochim Biophys Acta. 2014 Jun; 1843(6):1216-24. PMID: 24632071.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    40. Green T, Chen X, Ryan S, Asch AS, Ruiz-Echevarría MJ. TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells. Prostate. 2013 Oct; 73(14):1561-75. PMID: 23824605.
      Citations: 24     Fields:    Translation:HumansCells
    41. Dong L, Li Z, Leffler NR, Asch AS, Chi JT, Yang LV. Acidosis activation of the proton-sensing GPR4 receptor stimulates vascular endothelial cell inflammatory responses revealed by transcriptome analysis. PLoS One. 2013; 8(4):e61991. PMID: 23613998.
      Citations: 76     Fields:    Translation:HumansCells
    42. Overcash RF, Chappell VA, Green T, Geyer CB, Asch AS, Ruiz-Echevarría MJ. Androgen signaling promotes translation of TMEFF2 in prostate cancer cells via phosphorylation of the a subunit of the translation initiation factor 2. PLoS One. 2013; 8(2):e55257. PMID: 23405127.
      Citations: 13     Fields:    Translation:HumansCells
    43. Whelan JT, Hollis SE, Cha DS, Asch AS, Lee MH. Post-transcriptional regulation of the Ras-ERK/MAPK signaling pathway. J Cell Physiol. 2012 Mar; 227(3):1235-41. PMID: 21688267.
      Citations: 45     Fields:    Translation:HumansCells
    44. Chen A, Dong L, Leffler NR, Asch AS, Witte ON, Yang LV. Activation of GPR4 by acidosis increases endothelial cell adhesion through the cAMP/Epac pathway. PLoS One. 2011; 6(11):e27586. PMID: 22110680.
      Citations: 72     Fields:    Translation:HumansCells
    45. Chen X, Overcash R, Green T, Hoffman D, Asch AS, Ruiz-Echevarría MJ. The tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels. J Biol Chem. 2011 May 06; 286(18):16091-100. PMID: 21393249.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    46. Sigounas G, Hairr JW, Cooke CD, Owen JR, Asch AS, Weidner DA, Wiley JE. Role of benzo[alpha]pyrene in generation of clustered DNA damage in human breast tissue. Free Radic Biol Med. 2010 Jul 01; 49(1):77-87. PMID: 20347033.
      Citations: 5     Fields:    Translation:HumansCells
    47. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002 Nov 01; 100(9):3426-8. PMID: 12384448.
      Citations: 32     Fields:    Translation:HumansCells
    48. Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T, Asch AS. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat Med. 2001 Jul; 7(7):840-6. PMID: 11433350.
      Citations: 100     Fields:    Translation:HumansCells
    49. Arvanitakis L, Mesri EA, Nador RG, Said JW, Asch AS, Knowles DM, Cesarman E. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood. 1996 Oct 01; 88(7):2648-54. PMID: 8839859.
      Citations: 164     Fields:    Translation:HumansCells
    50. Rafii S, Shapiro F, Pettengell R, Ferris B, Nachman RL, Moore MA, Asch AS. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood. 1995 Nov 01; 86(9):3353-63. PMID: 7579438.
      Citations: 86     Fields:    Translation:HumansCells
    51. Rafii S, Shapiro F, Rimarachin J, Nachman RL, Ferris B, Weksler B, Moore MA, Asch AS. Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. Blood. 1994 Jul 01; 84(1):10-9. PMID: 7517203.
      Citations: 68     Fields:    Translation:HumansCells
    52. Posnett DN, Kabak S, Hodtsev AS, Goldberg EA, Asch A. T-cell antigen receptor V beta subsets are not preferentially deleted in AIDS. AIDS. 1993 May; 7(5):625-31. PMID: 8318171.
      Citations: 15     Fields:    Translation:HumansCells
    53. Asch AS, Leung LL, Polley MJ, Nachman RL. Platelet membrane topography: colocalization of thrombospondin and fibrinogen with the glycoprotein IIb-IIIa complex. Blood. 1985 Oct; 66(4):926-34. PMID: 2994782.
      Citations: 14     Fields:    Translation:HumansCells
    54. Nachmias V, Sullender J, Asch A. Shape and cytoplasmic filaments in control and lidocaine-treated human platelets. Blood. 1977 Jul; 50(1):39-53. PMID: 871525.
      Citations: 15     Fields:    Translation:HumansCells
    Asch's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (299)
    Explore
    _
    Co-Authors (28)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _